GeoVax Labs, Inc.

For the 9 months ended September 30, 2025, GeoVax reported revenue of $2.5 million versus $3.1 million in 2024, with no contract revenue in Q3 after the BARDA Project NextGen contract was terminated in April. Third-quarter R&D expense was $5.0 million versus $7.4 million a year ago, and 9-month R&D was $15.1 million versus $16.1 million. Third-quarter G&A was $1.3 million versus $1.2 million, and 9-month G&A was $4.6 million versus $3.8 million. Net loss was $6.3 million for the quarter versus $5.8 million in 2024, and $17.0 million year to date versus $16.7 million. Cash at September 30 was $5.0 million versus $5.5 million at December 31, 2024, after $16.5 million used in operating activities and $16.0 million from financing transactions. Management did not provide formal next-quarter or full-year revenue guidance; instead, it said priority spending will support CM04S1, GEO-MVA and Gedeptin and that it is seeking ways to extend cash runway.

David Dodd’s core message was that GeoVax sees multiple programs moving toward value-creating inflection points, with GEO-MVA getting the most near-term strategic attention because of the EMA path and broader government/stakeholder interest. He framed the company as pursuing expedited registration pathways, global commercialization potential, and partnerships that could accelerate development and distribution. His tone was upbeat and persistent, but he repeatedly tied execution speed to balance sheet strength and external support.

Mark Reynolds said the year-to-date revenue decline reflected the termination of the BARDA Project NextGen contract, which also meant no Q3 contract revenue. He highlighted lower R&D spending in 2025, mainly from discontinued BARDA-related costs and lower CM04S1 and Gedeptin trial/manufacturing costs, partly offset by higher GEO-MVA development costs ahead of 2026 clinical trials. He also noted higher G&A from personnel, investor relations, program expenses and stock-based compensation, and said cash was $5.0 million at quarter-end, with future cash needs likely to be directed first to CM04S1, GEO-MVA and Gedeptin. He said the company is considering strategic partnerships, nondilutive funding and additional common stock offerings to fund development and extend runway.

Analysts focused on whether GEO-MVA could be used commercially in an outbreak scenario before clinical trials, and management said it would not expect that, though it sees a possible role for emergency-use licensing through WHO under certain circumstances. Questions also centered on partnerships: management said it holds worldwide rights, intends to register broadly, and would consider region-specific collaborations if they create value. For GEO-MVA manufacturing and delivery, management said it is using the CEF platform with Oxford Biomedica for clinical supply and is evaluating needle-free delivery approaches such as microarray patches. On Gedeptin, management said it is open to discussions with other checkpoint inhibitor companies but is not yet in active, near-term expansion talks beyond pembrolizumab.